ALNY · Alnylam Pharmaceuticals Inc
United States · RS rating 12 · As of 2026-11-03
| Price | 159.89 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 14 / 21 / 14 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 4 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -55.4% |
| Sales growth Q/Q | -12.2% |
| Distance from 52-week high | +66.2% |
| Market cap (USD) | $41.9B |